What is mavyret medication cost off insurance?

what is mavyret medication cost off insurance
If you are concerned about the price of MAVYRET, you have choices. – * Cure is defined as no detectable hep C virus in the blood three months after therapy finishes. Individual outcomes might vary. As of January 2022, the advertised price, also known as the Wholesale Acquisition Cost (WAC), for one month of MAVYRET is $13,200.00.

If you have: You could pay:
$ 20
Medicaid $ 20 $20.00 or less per month, depending on state plan
Commercial Insurance (usually provided by employer) (Blue Cross Blue Shield, Aetna, etc) As little as $5 a month with MAVYRET Savings Card
Medicare: Part D $660.00-3,081.00 per month, depending on coverage phase Most Medicare patients have Standard Part D prescription coverage, which has different costs depending on deductibles and coverage gaps. An Insurance Specialist can help you understand what these costs mean to you, by calling 1-877-628-9738, Monthly out-of-pocket cost for MAVYRET may vary depending on patient’s other medication costs.
Medicare: Low-Income Subsidy (LIS) $9.85 per month starting January 1, 2022
Uninsured or having difficulty paying for your medication myAbbVie Assist provides AbbVie medicines to qualifying patients. Visit AbbVie.com/myAbbVieAssist or call 1-800-222-6885 to learn more.
Other Insurance (VA, DOD, TRICARE, others) Because coverage varies by plan, call 1-877-628-9738 to speak to an Insurance Specialist to find out how much MAVYRET will cost you.
*Important Details About Understanding Your Individual Costs: The chart above provides cost information based on what a person with the type of coverage listed may pay for a 4-week supply of MAVYRET. Your type of health or prescription insurance plan will determine exactly how much you will pay.

Exists a generic version of MAVYRET?

Currently, there are no generic alternatives to Mavyret. Most Medicare and insurance companies do not cover it, however manufacturer and drugstore discounts can help offset the cost.

According to AbbVie, the manufacturer, the list price of Mavyret (glecaprevir and pibrentasvir) pills for a 4-week supply is $13,200 or $26,400 for an 8-week treatment cycle. Nevertheless, dependent on your public or private insurance coverage and copayment, your out-of-pocket expense may be much less.

  1. AbbVie’s Patient Assistance Program may help reduce your costs, depending on your eligibility.
  2. Medicaid insurance often costs less than or equal to $20.00 per month, depending on the state plan.
  3. Depending on your coverage phase, the monthly premium can range from $660.00 to $2,847.00 for Medicare Part D beneficiaries.

Patients with Medicare Low-Income Subsidy will pay $8.95 per month. Mavyret pills are priced extremely reasonably compared to other authorized oral HCV therapies and may be your least expensive alternative. Check with your insurance provider to determine if Mavyret is covered.

Mavyret is often considered a speciality drug in the United States and may require access via a specialty pharmacy. AbbVie may be able to reduce your payment to as little as $5 if you have commercial insurance and obtain the Mavyret Savings Copay Card. Mavyret is a combined antiviral medication intended to limit the spread of hepatitis C virus (HCV) in the body.

Mavyret is licensed for the treatment of all six genotypes (1-6) of hepatitis C virus (HCV) in adults and children aged 12 and older or weighing at least 45 kg (without cirrhosis or with compensated cirrhosis).

How long is therapy with MAVYRET?

AbbVie Receives FDA Approval for MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Nave Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes NORTH CHICAGO, Ill., Sept.26, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global bio MAVYRET ® (glecaprevir/pibrentasvir) has been approved by the Food and Drug Administration (FDA) to decrease the once-daily treatment duration from 12 to 8 weeks in treatment-nave, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes (GT1-6).

MAVYRET was granted regulatory clearance in the United States in August 2017 as an 8-week, pan-genotypic therapy for treatment-naive HCV patients without cirrhosis. AbbVie’s vice president of general medicine and virology therapeutic area, Janet Hammond, M.D., Ph.D., stated that despite the fact that over 100,000 patients in the U.S.

have been given MAVYRET for chronic HCV, there are still a large number of patients who require alternatives. The label expansion was supported by findings from the Phase 3b EXPEDITION-8 project, a single-arm, open-label investigation investigating the safety and effectiveness of MAVYRET in treatment-nave individuals with GT1-6 chronic HCV with compensated cirrhosis.12 weeks following therapy, 98 percent (n=335/343) of patients in the trial had a sustained virologic response (SVR 12 ).

Access to shorter-term, 8-week treatment alternatives will help us get closer to the World Health Organization’s goal of eradicating chronic HCV by 2030, according to Robert S. Brown, Jr., M.D., Gladys and Roland Harriman professor of medicine at Weill Cornell Medical Center. In EXPEDITION-8, one recurrence was documented among 336 treated patients, and no patients terminated therapy owing to adverse effects.1,2 Fatigue (8%), pruritus (7%), and headache (6%) were the adverse effects reported by at least 5% of compensated cirrhotic patients (n = 343).1 Data from cohort one (GT1,2,4,5,6) were presented at The Liver Meeting ® 2018 hosted by the American Association for the Study of Liver Diseases (AASLD) last year, and data from cohort two (GT3) will be presented at a forthcoming medical conference.

EXPEDITION-8 is a single-arm, open-label, Phase 3b research in treatment-nave, GT1-6 chronic HCV patients with compensated cirrhosis (n=343) who received MAVYRET for 8 weeks. Sustained virologic response 12 weeks after treatment (SVR 12) rates in patients across all genotypes in a per-protocol (PP) and intent-to-treat (ITT) population versus respective historical SVR 12 rates based on the efficacy of MAVYRET for 12 weeks in treatment-naive patients with compensated cirrhosis are the primary endpoints.

The most important secondary efficacy objectives are the percentages of GT1- 6 patients who achieve SVR12 in PP and ITT populations. Additional information on MAVYRET’s clinical studies is accessible here. About MAVYRET ® (glecaprevir/pibrentasvir) 1 The U.S. Food and Drug Administration has authorized MAVYRET ®.

FDA for the treatment of chronic hepatitis C virus (HCV) infection in adults across all main genotypes (GT1-6). MAVYRET is a pan-genotypic, once-day, ribavirin-free medication that combines glecaprevir (100mg), an NS3/4A protease inhibitor, and pibrentasvir (40mg), an NS5A inhibitor, dosed as three tablets taken once daily with meals.

  1. MAVYRET is an 8-week, pan-genotypic alternative for treatment-naive patients without cirrhosis or with compensated cirrhosis, who account for the vast majority of HCV-positive individuals.
  2. MAVYRET is also approved as a treatment for patients with specific treatment challenges, including those (GT1) not cured by prior treatment experience with either a protease inhibitor or NS5A inhibitor (but not both) and those with limited treatment options, such as those with severe chronic kidney disease (CKD) or genotype 3 chronic HCV.

MAVYRET is an authorized pan-genotypic therapy for all phases of chronic kidney disease (CKD). Glecaprevir (GLE) was discovered during AbbVie and Enanta Pharmaceuticals’ (NASDAQ: ENTA) continuing partnership for HCV protease inhibitors and regimens containing protease inhibitors.

Complete prescription information is available. Use and Essential Safety Instructions MAVYRET ® (glecaprevir and pibrentasvir) tablets are a prescription treatment for individuals with chronic hepatitis C virus (hep C) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.

IMPORTANT SAFETY INFORMATION What is the most vital information regarding MAVYRET? Hepatitis B (hep B) viral reactivation: Before beginning MAVYRET therapy, a physician will do blood tests to detect hep B infection. If a person has previously been infected with hep B, hep B might become active again during or after treatment with MAVYRET for hep C.

Hep B that reactivates (also known as reactivation) can result in severe liver issues, including liver failure and death. A physician will follow patients who are at risk for hep B reactivation during and after treatment with MAVYRET. MAVYRET should not be taken if: Have certain liver disorders Are you currently taking atazanavir or rifampin? What should patients notify their physician before using MAVYRET? If they have had hepatitis B, liver disorders other than hepatitis C, HIV-1 infection, a liver or kidney transplant, or any other medical condition.

If they are nursing or plan to breastfeed, or if they are pregnant or plan to get pregnant. It is unknown whether MAVYRET will affect an unborn child or enter breast milk. If using MAVYRET, a physician should be informed about the best approach to feed a baby.

  • Regarding the prescription and over-the-counter medications, vitamins, and herbal supplements they are taking.
  • MAVYRET and other medications may interact adversely.
  • This can lead to excessive or inadequate levels of MAVYRET or other medications in the body.
  • This may alter the effectiveness of MAVYRET or other medications or produce negative effects.

No new medication should be taken without first consulting a physician. A physician will offer instructions on the compatibility of MAVYRET with other medications. What are the potential adverse reactions of MAVYRET? Prior to beginning therapy with MAVYRET, there is a rare risk of increasing liver issues, liver failure, and death in patients with severe liver disease.

  • During therapy with MAVYRET, their doctor will monitor patients for signs and symptoms of increasing liver disorders.
  • They should contact their doctor immediately if they experience any of the following symptoms: nausea; fatigue; yellowing of the skin or whites of the eyes; abnormal bleeding or bruising; confusion; dark, black, or bloody stool; loss of appetite; diarrhea; dark or brown (tea-colored) urine; swelling or pain on the upper right side of the abdomen (abdomen); sleepiness; vomiting of blood; or dizziness.

The most prevalent adverse effects of MAVYRET are headache and fatigue. These are not all of the possible MAVYRET side effects. If a side effect is troublesome or persistent, a physician should be informed. This is the most vital information on MAVYRET.

For further information, individuals should see a physician or healthcare professional. The FDA encourages individuals to report adverse effects of prescription medications. Call or visit 1-800-FDA-1088. Please view the including the. People who cannot afford their medications should visit AbbVie.com/myAbbVieAssist for additional information.

Regarding AbbVie AbbVie is a worldwide biopharmaceutical firm devoted to discovering novel, advanced medicines for some of the world’s most difficult and life-threatening diseases. The company’s objective is to significantly enhance therapies in four key therapeutic areas: immunology, cancer, virology, and neurology by using its knowledge, devoted personnel, and distinctive approach to innovation.

AbbVie professionals work every day in more than 75 countries to create health solutions for people across the world. Please visit for more information about AbbVie. Follow on Twitter or Facebook. For further details, please visit. Forward-Looking Statements For purposes of the Private Securities Litigation Reform Act of 1995, many statements in this press release are forward-looking or may be deemed forward-looking.

Forward-looking statements are often identified by terms such as “believe,” “expect,” “anticipate,” “project,” and similar phrases. AbbVie warns that these forward-looking statements are subject to risks and uncertainties that might cause actual results to differ considerably from those projected.

  1. These risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other goods, inherent problems in the research and development process, unfavorable litigation or government action, and changes in laws and regulations applicable to our business.
  2. Item 1A, “Risk Variables,” of AbbVie’s 2017 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, contains further information on the economic, competitive, governmental, technical, and other factors that may influence AbbVie’s operations.

Except as required by law, AbbVie assumes no duty to disseminate publicly any changes to forward-looking statements as a consequence of later events or developments.

*Refers to patients with Child-Pugh A cirrhosis score.
†Liver or kidney transplant recipients are not eligible for an 8-week regimen.
**Patients who achieve a sustained virologic response at 12 weeks post treatment (SVR) are considered cured of hepatitis C.
‡ Based on retail and non-retail prescription data from IQVIA week ending 8/11/17-8/2/19.3
1 MAVYRET ® tablets (glecaprevir/pibrentasvir) Prescribing Information. Chicago, U.S. AbbVie Inc.
2 Brown RS, Hezode C, Wang S, et al. Preliminary Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1–6 Infection and Compensated Cirrhosis: The EXPEDITION-8 Study. Presented at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, U.S., November 13, 2018.
3 Data on file. AbbVie Inc. IQVIA. National Prescription Audit (NPA) week ending 8/11/2017 to week ending 8/2/2019, Weekly Sales Perspective (WSP) and Longitudinal Prescription Claims (LRx) week ending 8/4/2017 to week ending 7/26/2019. August 2019. (IQVIA, all rights reserved).

AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Reduce Treatment Duration to Eight Weeks for Patients with Chronic Hepatitis C with Compensated Cirrhosis Across All Genotypes

This includes not sharing needles and engaging in safe sexual practices. Inform your healthcare practitioner if you have a history of liver disease or any other medical disorders, such as HIV.

What’s the difference between Epclusa and MAVYRET?

Epclusa and Mavyret are expensive brand-name drugs. Epclusa is available as a generic medication. Mavyret is presently only accessible as a brand-name medication. Typically, brand-name drugs are more expensive than generics. Epclusa often costs more than Mavyret. Your real cost for any medication will depend on your insurance coverage.

Both Mavyret and Harvoni are direct-acting antiviral treatments for hepatitis C virus (HCV) infection. Mavyret is available as tablets or oral pellets and includes glecaprevir and pibrentasvir. Harvoni is also available in tablet and pellet form and contains ledipasvir and sofosbuvir.

  1. Reported benefits of Mavyret over Harvoni include the number of HCV genotypes it treats, the duration of treatment, and the cost of a treatment course.
  2. Mavyret is authorized to treat chronic HCV genotypes 1, 2, 3, 4, 5 or 6 infection in patients without or with compensated cirrhosis (Child-Pugh A), but Harvoni is only authorized to treat genotypes 1, 4, 5 or 6.

In addition, Mavyret is normally administered for only eight weeks, while Harvoni is administered for twelve. The cost is another advantage of Mavyret. When Mavyret was originally authorized in 2017, the drug’s manufacturer, AbbVie, opted for a pricing approach that made it less expensive than other choices and helped it to rapidly increase its market share.

What are MAVYRET’s long-term negative effects?

Long-term Mavyret side effects If you have previously been infected with HBV, this is when the virus becomes active again. In certain individuals, HBV reactivation has resulted in fulminant hepatitis (acute liver failure), liver failure, and death.